Mark J. Ratain to Cytochrome P-450 Enzyme System
This is a "connection" page, showing publications Mark J. Ratain has written about Cytochrome P-450 Enzyme System.
Connection Strength
0.306
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.075
-
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec; 78(6):559-81.
Score: 0.064
-
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep; 32(9):930-6.
Score: 0.059
-
Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998 Sep; 34(10):1493-9.
Score: 0.039
-
Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
Score: 0.036
-
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
Score: 0.018
-
Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb; 35(2):228-33.
Score: 0.017